OPIOID IMPACT
We have seen significant decreases in opioid use, with the majority eliminating all opioid use while using our product. Further, the formulation modified for addiction has shown good results with every individual who has tried it so far.
We truly believe these two products can impact the opioid crisis significantly by offering a non addictive alternative to opioids thereby reducing the incidence of addiction as well as treating current individuals with abuse disorder allowing for rapid cessation of opioid use.
A Non-Addictive Alternative to Opioids
Opioid use disorder affects over 2.5 million Americans, with 75% developing dependence after prescription use, often post-injury or surgery. Every day, approximately 3,000 people misuse opioids for the first time, and 220 lives are lost.
Our formulation was designed to provide pain relief without addictive potential. A modified version, targeting pathways involved in addiction, was tested in an individual with long term methadone use. After multiple failed attempts to quit, she experienced significantly reduced withdrawal symptoms and successfully discontinued use within just over two weeks. Further, individuals with severe withdrawal symptoms from a natural opioid were relieved from the symptoms and able to cease the compound in 1-3 days.
Our Mission: Expanding Access to Non-Opioid Pain Relief
-
Bringing this innovative, non-addictive formulation to market
-
Delivering meaningful relief to CRPS patients as soon as possible
-
Expanding access to individuals living with chronic pain
-
Supporting efforts to combat the opioid crisis
-
Establishing a nonprofit to assist those unable to afford treatment
We are allowing investments with a goal of raising minimally $80,000. The vehicle is designed for conversion to a percentage of the value of the company at the time of conversion. The return on investment is capped at a 25 fold return.
The minimum investment is $500 and the maximum is $4,000. Each $500 gives the right to convert for 0.125% of the value of the company at the time of conversion.
As an example with a $4,000 investment
-
This gives the right to convert for 1% of the company value.
-
Company valued at $10 Million or an estimated 0.03% of the chronic pain market at the time of conversion would give a $100,000 return
-
For CRPS in general capturing 10% of the US market would give an estimated company valuation of $50 Million.
Bringing the formulation to market—with the clinical data required for FDA approval—requires over $1 million in funding for manufacturing, testing, and regulatory compliance.
Early results suggest this solution has broad potential to support pain relief across conditions—offering hope to those with limited treatment options.